Stocks in play: Titan Medical Inc.

Announced today a corporate update and is also providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-2003. As a result of the strategic review process announced on November 30, 2022, the Board of Directors of Titan have approved a strategic transition in the Company’s business from the development and commercialization of robotic-assisted surgery technologies to evaluating new opportunities to further develop and license its intellectual property. Titan continues to retain the rights necessary to develop and commercialize RAS technologies, should it choose to do so, including the two-instrument Enos single-access RAS system and, as announced on January 9, 2023, a three-instrument single-access RAS system that builds on the Enos System technologies. Titan Medical Inc. shares T.TMD are trading down $0.01 at $0.25.